Baillie Gifford & Co
ADAP

Baillie Gifford & Co’s Adaptimmune Therapeutics ADAP Stock Holding History

Baillie Gifford & Co’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-11,819,095
Closed -$6.37M – 267
2024
Q4 		$6.37M Sell
11,819,095
-4,956,765
-30% -$3.61M ﹤0.01% 223
2024
Q3 		$15.9M Buy
16,775,860
+1,626,657
+11% +$1.85M 0.01% 191
2024
Q2 		$14.8M Sell
15,149,203
-722,672
-5% -$793K 0.01% 193
2024
Q1 		$25.1M Sell
15,871,875
-40,265
-0.3% -$48.6K 0.02% 180
2023
Q4 		$12.6M Sell
15,912,140
-1,235,269
-7% -$696K 0.01% 208
2023
Q3 		$13.4M Sell
17,147,409
-28,726
-0.2% -$24.1K 0.01% 204
2023
Q2 		$15.9M Buy
17,176,135
+64,133
+0.4% +$76.5K 0.01% 194
2023
Q1 		$18.7M Sell
17,112,002
-57,937
-0.3% -$89.7K 0.02% 187
2022
Q4 		$25.1M Buy
17,169,939
+2,505,003
+17% +$4.06M 0.03% 180
2022
Q3 		$15.8M Sell
14,664,936
-656,410
-4% -$1.21M 0.02% 197
2022
Q2 		$26M Sell
15,321,346
-59,192
-0.4% -$102K 0.03% 182
2022
Q1 		$31.7M Buy
15,380,538
+1,624,186
+12% +$4.38M 0.02% 191
2021
Q4 		$51.6M Buy
13,756,352
+931,372
+7% +$4.24M 0.03% 184
2021
Q3 		$66.3M Buy
12,824,980
+1,128,061
+10% +$5.06M 0.03% 165
2021
Q2 		$49.8M Buy
11,696,919
+229,402
+2% +$1.11M 0.02% 192
2021
Q1 		$60.9M Buy
11,467,517
+1,109,737
+11% +$6.35M 0.03% 164
2020
Q4 		$55.8M Buy
10,357,780
+3,279,717
+46% +$17.8M 0.03% 160
2020
Q3 		$56.5M Buy
7,078,063
+1,788,394
+34% +$15.7M 0.04% 146
2020
Q2 		$53M Buy
5,289,669
+935,646
+21% +$5.88M 0.04% 133
2020
Q1 		$11.8M Buy
4,354,023
+66,478
+2% +$221K 0.01% 163
2019
Q4 		$5.14M Buy
4,287,545
+122,738
+3% +$131K 0.01% 188
2019
Q3 		$6.29M Buy
4,164,807
+20,967
+0.5% +$49K 0.01% 186
2019
Q2 		$16.7M Buy
4,143,840
+304,650
+8% +$1.24M 0.02% 166
2019
Q1 		$16.5M Buy
3,839,190
+139,669
+4% +$650K 0.02% 169
2018
Q4 		$21.3M Buy
3,699,521
+281,894
+8% +$2.08M 0.03% 154
2018
Q3 		$46.3M Buy
3,417,627
+384,366
+13% +$4.03M 0.05% 121
2018
Q2 		$36M Buy
3,033,261
+467,852
+18% +$5.83M 0.04% 124
2018
Q1 		$28.8M Buy
2,565,409
+644,816
+34% +$5.64M 0.03% 125
2017
Q4 		$12.8M Buy
1,920,593
+541,289
+39% +$4.18M 0.02% 155
2017
Q3 		$11.3M Buy
1,379,304
+55,996
+4% +$350K 0.01% 156
2017
Q2 		$5.94M Buy
1,323,308
+402,324
+44% +$2.1M 0.01% 178
2017
Q1 		$5.08M Hold
920,984
– – 0.01% 171
2016
Q4 		$3.73M Hold
920,984
– – 0.01% 183
2016
Q3 		$6.49M Buy
920,984
+491,284
+114% +$3.75M 0.01% 172
2016
Q2 		$3.5M Hold
429,700
– – 0.01% 180
2016
Q1 		$3.49M Buy
+429,700
New +$3.51M 0.01% 181

Other funds holding ADAP

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Baillie Gifford & Co's ADAP Position: Q1 2025 in Review

Baillie Gifford & Co sold out of Adaptimmune Therapeutics (ADAP) in Q1 2025, closing a stake of 11,819,095 shares — an estimated $6.37M sold.

Baillie Gifford & Co first reported a position in ADAP in Q1 2016 and held it in 36 quarters. The position peaked at $66.3M in Q3 2021. 67 funds tracked by Wall St. Rank hold ADAP as of Q1 2025.

  • Baillie Gifford & Co reported no remaining Adaptimmune Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Baillie Gifford & Co sold 11,819,095 Adaptimmune Therapeutics shares in Q1 2025, an estimated $6.37M.
  • Baillie Gifford & Co first reported a position in Adaptimmune Therapeutics in Q1 2016 and held it in 36 quarters.
  • Baillie Gifford & Co's Adaptimmune Therapeutics position peaked at $66.3M in Q3 2021.
  • 67 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2025.

Based on Baillie Gifford & Co's 13F filing for Q1 2025, filed 7 May 2025.